Genmab News

Genmab Announces Presentation Of Multiple Abstracts On Epcoritamab At 2024 European Hematology Association Congress On June 13-16

Genmab Announces Presentation Of Multiple Abstracts On Epcoritamab At 2024 European Hematology Association Congress On June 13-16

BenzingaMay 14 09:10

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

Media ReleaseCOPENHAGEN, Denmark; May 14, 2024 Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development programThree oral pres

GlobeNewswireMay 14 09:02

Watching Genmab; Shares Trading Higher After Novo Nordisk Announced Results From The FRONTIER 2 Trial In People Aged 12 Years Or Older With Haemophilia A

Watching Genmab; Shares Trading Higher After Novo Nordisk Announced Results From The FRONTIER 2 Trial In People Aged 12 Years Or Older With Haemophilia A

BenzingaMay 13 11:00

Genmab A/S Details Capital and Corporate Structure

TipRanksMay 8 12:58

6-K: Report of foreign private issuer (related to financial reporting)

Futu NewsMay 8 11:48 · Announcements

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. The increase is

GlobeNewswireMay 7 13:27

Genmab Advances Share Buy-back Program

TipRanksMay 6 10:57

Transactions in Connection With Share Buy-back Program

Yahoo FinanceMay 6 09:01

Zaiding Pharmaceuticals announced that partners Pfizer and Genmab have jointly announced that the US Food and Drug Administration (FDA) has approved TIVDAK (tisotumab vedotin-tftv)'s supplementary biologics license application (SBLA) to fully approve it f

Zaiding Pharmaceuticals announced that partners Pfizer and Genmab have jointly announced that the US Food and Drug Administration (FDA) has approved TIVDAK (tisotumab vedotin-tftv)'s supplementary biologics license application (SBLA) to fully approve it for the treatment of patients with recurrent or metastatic cervical cancer whose disease progresses during or after chemotherapy.

Zhitong FinanceMay 6 03:20

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Cigna (CI) and Genmab (GMAB)

TipRanksMay 3 06:38

Genmab (GMAB) Receives a Buy From Truist Financial

TipRanksMay 3 06:30

Optimistic Outlook for Genmab: Strategic Growth and Product Performance Underpin Buy Rating

TipRanksMay 3 06:00

Earnings Call Summary | Genmab(GMAB.US) Q1 2024 Earnings Conference

The following is a summary of the Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript:Financial Performance:Genmab reported strong growth across its portfolio in Q1 2024, with notable gain in DARZALEX

Futu NewsMay 3 03:50 · Conference Call

Genmab Posts Q1 Net Profit Surge; Revenue Jumps

Genmab (GMAB.CO) said Thursday net profit for the first quarter surged as revenue jumped year over year. Net profit for the three months ended March 31 was 1.33 billion Danish kroner, compared with 21

MT NewswiresMay 2 21:48

Genmab (GMAB.US): The 2024 Q1 financial report achieved revenue of US$600.4 million, previous value of US$411.3 million, expected value of US$577.5 million; earnings per share were US$0.29, previous value was US$0.05, and expected value was US$0.14.

Genmab (GMAB.US): The 2024 Q1 financial report achieved revenue of US$600.4 million, previous value of US$411.3 million, expected value of US$577.5 million; earnings per share were US$0.29, previous value was US$0.05, and expected value was US$0.14.

Zhitong FinanceMay 2 11:40

Genmab Reports Q1 Results

Seeking AlphaMay 2 10:05

Genmab Q1 2024 Revenue $604.25M

Genmab Q1 2024 Revenue $604.25M

BenzingaMay 2 10:05

Press Release: Genmab Announces Financial Results for the First Quarter of 2024

Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights -- The U.S. Food and Drug

Dow JonesMay 2 10:01

Genmab Q1 2024 Earnings Preview

Seeking AlphaMay 1 13:28

Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer

Pfizer (PFE) and Genmab (GMAB) said Monday that the US Food and Drug Administration approved a supplemental biologics license application for Tivak to treat patients with recurrent or metastatic cervi

MT NewswiresApr 30 10:16